Research ExplorerPublicationsActive surveillance for prostate cancer: comparison between ...

Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies

Standard

Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. / Luzzago, Stefano; Piccinelli, Mattia Luca; Marvaso, Giulia; Laukhtina, Ekaterina; Miura, Noriyoshi; Schuettfort, Victor M; Mori, Keiichiro; Aydh, Abdulmajeed; Ferro, Matteo; Mistretta, Francesco A; Fusco, Nicola; Petralia, Giuseppe; Jereczek-Fossa, Barbara A; Shariat, Shahrokh F; Karakiewicz, Pierre I; de Cobelli, Ottavio; Musi, Gennaro.

In: WORLD J UROL, Vol. 40, No. 2, 02.2022, p. 443-451.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Luzzago, S, Piccinelli, ML, Marvaso, G, Laukhtina, E, Miura, N, Schuettfort, VM, Mori, K, Aydh, A, Ferro, M, Mistretta, FA, Fusco, N, Petralia, G, Jereczek-Fossa, BA, Shariat, SF, Karakiewicz, PI, de Cobelli, O & Musi, G 2022, 'Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies', WORLD J UROL, vol. 40, no. 2, pp. 443-451. https://doi.org/10.1007/s00345-021-03864-6

APA

Luzzago, S., Piccinelli, M. L., Marvaso, G., Laukhtina, E., Miura, N., Schuettfort, V. M., Mori, K., Aydh, A., Ferro, M., Mistretta, F. A., Fusco, N., Petralia, G., Jereczek-Fossa, B. A., Shariat, S. F., Karakiewicz, P. I., de Cobelli, O., & Musi, G. (2022). Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. WORLD J UROL, 40(2), 443-451. https://doi.org/10.1007/s00345-021-03864-6

Vancouver

Luzzago S, Piccinelli ML, Marvaso G, Laukhtina E, Miura N, Schuettfort VM et al. Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. WORLD J UROL. 2022 Feb;40(2):443-451. https://doi.org/10.1007/s00345-021-03864-6

Bibtex

@article{566f2114121941459da263a551795cf4,
title = "Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies",
abstract = "PURPOSE: To test discontinuation rates during Active Surveillance (AS) in patients diagnosed with incidental prostate cancers (IPCa) vs. tumors diagnosed at prostate biopsies (BxPCa).METHODS: Retrospective single center analysis of 961 vs. 121 BxPCa vs. IPCa patients (2008-2020). Kaplan-Meier plots and multivariable Cox regression models tested four different outcomes: (1) any-cause discontinuation; (2) discontinuation due to ISUP GG upgrading; (3) biopsy discontinuation due to ISUP GG upgrading or > 3 positive cores; (4) biopsy discontinuation or suspicious extraprostatic extension at surveillance mpMRI. Then, multivariable logistic regression models tested rates of clinically significant PCa (csPCa) (ISUP GG ≥ 3 or pT ≥ 3a or pN1) after radical prostatectomy (RP).RESULTS: Median time follow-up was 35 (19-64) months. IPCa patients were at lower risk of any-cause (3-year survival: 79.3 vs. 66%; HR: 0.5, p = 0.001) and biopsy/MRI AS discontinuation (3-year survival: 82.3 vs. 72.7%; HR: 0.5, p = 0.001), compared to BxPCa patients. Conversely, IPCa patients exhibited same rates of biopsy discontinuation and ISUP GG upgrading over time, relative to BxPCa. In multivariable logistic regression models, IPCa patients were associated with higher rates of csPCa at RP (OR: 1.4, p = 0.03), relative to their BxPCa counterparts.CONCLUSION: AS represents a safe management strategy for IPCa. Compared to BxPCa, IPCa patients are less prone to experience any-cause and biopsy/MRI AS discontinuation. However, the two mentioned groups present similar rates of biopsy discontinuation and ISUP GG upgrading over time. In consequence, tailored AS protocols with scheduled repeated surveillance biopsies should be offered to all newly diagnosed IPCa patients.",
author = "Stefano Luzzago and Piccinelli, {Mattia Luca} and Giulia Marvaso and Ekaterina Laukhtina and Noriyoshi Miura and Schuettfort, {Victor M} and Keiichiro Mori and Abdulmajeed Aydh and Matteo Ferro and Mistretta, {Francesco A} and Nicola Fusco and Giuseppe Petralia and Jereczek-Fossa, {Barbara A} and Shariat, {Shahrokh F} and Karakiewicz, {Pierre I} and {de Cobelli}, Ottavio and Gennaro Musi",
note = "{\textcopyright} 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",
year = "2022",
month = feb,
doi = "10.1007/s00345-021-03864-6",
language = "English",
volume = "40",
pages = "443--451",
journal = "WORLD J UROL",
issn = "0724-4983",
publisher = "Springer",
number = "2",

}

RIS

TY - JOUR

T1 - Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies

AU - Luzzago, Stefano

AU - Piccinelli, Mattia Luca

AU - Marvaso, Giulia

AU - Laukhtina, Ekaterina

AU - Miura, Noriyoshi

AU - Schuettfort, Victor M

AU - Mori, Keiichiro

AU - Aydh, Abdulmajeed

AU - Ferro, Matteo

AU - Mistretta, Francesco A

AU - Fusco, Nicola

AU - Petralia, Giuseppe

AU - Jereczek-Fossa, Barbara A

AU - Shariat, Shahrokh F

AU - Karakiewicz, Pierre I

AU - de Cobelli, Ottavio

AU - Musi, Gennaro

N1 - © 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

PY - 2022/2

Y1 - 2022/2

N2 - PURPOSE: To test discontinuation rates during Active Surveillance (AS) in patients diagnosed with incidental prostate cancers (IPCa) vs. tumors diagnosed at prostate biopsies (BxPCa).METHODS: Retrospective single center analysis of 961 vs. 121 BxPCa vs. IPCa patients (2008-2020). Kaplan-Meier plots and multivariable Cox regression models tested four different outcomes: (1) any-cause discontinuation; (2) discontinuation due to ISUP GG upgrading; (3) biopsy discontinuation due to ISUP GG upgrading or > 3 positive cores; (4) biopsy discontinuation or suspicious extraprostatic extension at surveillance mpMRI. Then, multivariable logistic regression models tested rates of clinically significant PCa (csPCa) (ISUP GG ≥ 3 or pT ≥ 3a or pN1) after radical prostatectomy (RP).RESULTS: Median time follow-up was 35 (19-64) months. IPCa patients were at lower risk of any-cause (3-year survival: 79.3 vs. 66%; HR: 0.5, p = 0.001) and biopsy/MRI AS discontinuation (3-year survival: 82.3 vs. 72.7%; HR: 0.5, p = 0.001), compared to BxPCa patients. Conversely, IPCa patients exhibited same rates of biopsy discontinuation and ISUP GG upgrading over time, relative to BxPCa. In multivariable logistic regression models, IPCa patients were associated with higher rates of csPCa at RP (OR: 1.4, p = 0.03), relative to their BxPCa counterparts.CONCLUSION: AS represents a safe management strategy for IPCa. Compared to BxPCa, IPCa patients are less prone to experience any-cause and biopsy/MRI AS discontinuation. However, the two mentioned groups present similar rates of biopsy discontinuation and ISUP GG upgrading over time. In consequence, tailored AS protocols with scheduled repeated surveillance biopsies should be offered to all newly diagnosed IPCa patients.

AB - PURPOSE: To test discontinuation rates during Active Surveillance (AS) in patients diagnosed with incidental prostate cancers (IPCa) vs. tumors diagnosed at prostate biopsies (BxPCa).METHODS: Retrospective single center analysis of 961 vs. 121 BxPCa vs. IPCa patients (2008-2020). Kaplan-Meier plots and multivariable Cox regression models tested four different outcomes: (1) any-cause discontinuation; (2) discontinuation due to ISUP GG upgrading; (3) biopsy discontinuation due to ISUP GG upgrading or > 3 positive cores; (4) biopsy discontinuation or suspicious extraprostatic extension at surveillance mpMRI. Then, multivariable logistic regression models tested rates of clinically significant PCa (csPCa) (ISUP GG ≥ 3 or pT ≥ 3a or pN1) after radical prostatectomy (RP).RESULTS: Median time follow-up was 35 (19-64) months. IPCa patients were at lower risk of any-cause (3-year survival: 79.3 vs. 66%; HR: 0.5, p = 0.001) and biopsy/MRI AS discontinuation (3-year survival: 82.3 vs. 72.7%; HR: 0.5, p = 0.001), compared to BxPCa patients. Conversely, IPCa patients exhibited same rates of biopsy discontinuation and ISUP GG upgrading over time, relative to BxPCa. In multivariable logistic regression models, IPCa patients were associated with higher rates of csPCa at RP (OR: 1.4, p = 0.03), relative to their BxPCa counterparts.CONCLUSION: AS represents a safe management strategy for IPCa. Compared to BxPCa, IPCa patients are less prone to experience any-cause and biopsy/MRI AS discontinuation. However, the two mentioned groups present similar rates of biopsy discontinuation and ISUP GG upgrading over time. In consequence, tailored AS protocols with scheduled repeated surveillance biopsies should be offered to all newly diagnosed IPCa patients.

U2 - 10.1007/s00345-021-03864-6

DO - 10.1007/s00345-021-03864-6

M3 - SCORING: Journal article

C2 - 34687344

VL - 40

SP - 443

EP - 451

JO - WORLD J UROL

JF - WORLD J UROL

SN - 0724-4983

IS - 2

ER -